Valproic Acid expanded cord blood stem cells

Valproic Acid expanded cord blood stem cells is an experimental cellular therapy developed at the Icahn School of Medicine at Mount Sinai. The product consists of umbilical cord blood-derived CD34+ hematopoietic stem cells that have been expanded ex vivo for seven days in the presence of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor. This expansion process is designed to increase the number of primitive hematopoietic stem cells and lineage-committed precursors, addressing the primary limitation of low cell dose in single cord blood units which often leads to delayed engraftment and increased transplant-related mortality. The therapy is intended for use in adults with high-risk hematological malignancies, such as acute myeloid leukemia and myelodysplastic syndromes, who are undergoing allogeneic hematopoietic stem cell transplantation with conditioning regimens that include total body irradiation (TBI).

Other names

VPA-expanded cord bloodVPA-expanded CD34+ cellsValproic Acid expanded hematopoietic stem cellsVPA-expanded UCB